New data from the UK’s Transform trial highlights a stark health disparity: black men develop prostate cancer at twice the rate of white men and experience significantly higher mortality. Despite this elevated risk, black populations have historically been excluded or underrepresented in cancer screening trials. The NHS is correcting this inequity by reducing the screening age for black men to 50—a full decade earlier than standard protocols. This evidence-based adjustment reflects emerging research demonstrating that aggressive disease manifestation occurs earlier in black men. The Transform trial enrolls 300,000 participants using dual diagnostic methods: PSA blood testing combined with MRI imaging for enhanced accuracy. This targeted approach recognizes that one-size-fits-all screening protocols fail vulnerable populations most likely to benefit from early detection. Read the full article on GMJ Newsroom.
Was this article helpful?
